Apollo Hospitals Q2 FY27 Earnings Call: Revenue Jumps 23% To Rs. 7,615 Cr, Demerger On Track For Q4 FY27 (APOLLOHOSP)

Apollo Hospitals Enterprise Ltd held its Q2 FY27 earnings call on November 04, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Broad-Based Growth Across All Three Verticals

• Consolidated revenue of Rs.7,615 crore (+23% YoY) — Q2 FY 2026-2027 EBITDA of Rs.1,191 crore (+29% YoY) with margin at 15.6% vs 14.9% in Q2 FY 2025-2026; PAT of Rs.630 crore (+32% YoY).
• All three verticals delivered double-digit growth — healthcare services, HealthCo and AHLL each grew in double digits in Q2 FY 2026-2027.
• H1 FY 2026-2027 consolidated revenue of Rs.14,547 crore (+22% YoY) — EBITDA Rs.2,268 crore (+29%); PAT Rs.1,211 crore (+33%); healthcare services revenue Rs.7,467 crore (+22%); HealthCo and AHLL revenue growth of 22% and 19% respectively.
• AHLL swung to profitability — Q2 FY 2026-2027 revenue Rs.429 crore (+20% YoY); EBITDA Rs.61 crore at 14.3% margin vs 9.5% in Q2 FY 2025-2026; PAT Rs.26 crore vs a loss of Rs.4 crore in Q2 FY 2025-2026.
• Apollo HealthCo PAT of Rs.118 crore vs Rs.73 crore — Q2 FY 2026-2027 revenue Rs.3,286 crore (+23% YoY); EBITDA Rs.193 crore (+75% YoY); the 24/7 digital business turned cash positive with Rs.1 crore cash profit vs a Rs.39 crore loss in Q2 FY 2025-2026.

High-Acuity Mix, IPS Rebound and Bed Expansion

• Inpatient volumes +14% YoY — Q2 FY 2026-2027 occupancy at 73%; average revenue per patient Rs.1,86,880 (+8% YoY); insurance and self-pay together at 82% of inpatient revenues.
• High-acuity specialties grew 22% YoY — cardiac, oncology, neurosciences, gastro, orthopedics and transplant constituted 61% of inpatient revenues in Q2 FY 2026-2027.
• International patient revenues +37% YoY — IPS grew 35-36% in Q2 FY 2026-2027; Bangladesh flows rebounded to ~85-90% of peak on an annualized basis, with additional growth from developed markets including Europe; management only "hoped" the momentum builds (period unspecified).
• Africa is a key new-market focus — Apollo has set up information centers in Tanzania, Kenya and other geographies and is seeing good growth from these markets.
• 1,395 census beds planned across FY 2026-2027 — 520 commissioned to date; Gurugram to be commissioned in Q3 FY 2026-2027, with all 1,400 beds targeted to be fully operationalized over the next 12 months (through ~FY 2027-2028).
• ~320 additional beds in the FY 2027-2028 and FY 2028-2029 pipeline — expansions at Jubilee Hills, Secunderabad, Bangalore, Mysore and Indore to take the total to ~1,800 beds; remaining pipeline launches expected mostly in FY30 and FY31.
• New-hospital drag of Rs.35 crore EBITDA loss — Q2 FY 2026-2027 new hospitals revenue of Rs.135 crore on ramp-up of newly commissioned capacity and hiring of new doctors; established hospitals EBITDA Rs.971 crore (+22% YoY) with margins up 61 bps to 25.8%.

Cash Break-Even Achieved; Insurance Deliberately Slowed

• Apollo Pharmacy grew ~28% in FY 2026-2027 and ~14% sequentially in Q2 — diagnostics grew ~17% in FY 2026-2027 with ~12% sequential growth in Q2 FY 2026-2027; both are digital businesses fronted by Apollo 24/7, evaluated on GMV.
• Management "reasonably confident" pharmacy and diagnostics will keep growing at least at current rates — period unspecified; consults revenue rose ~7% sequentially in Q2 FY 2026-2027, with a "hospital mode" being built alongside the hospitals division.
• Apollo Circle posted ~11% sequential growth in Q2 FY 2026-2027 — core paying loyal customer base expanding, driven by rising customer counts and cross-sell into the pharmacy base.
• Insurance distribution being deliberately recalibrated — after ~4% QoQ growth in Q1 FY 2026-2027, management is "putting the brakes on" in Q2 FY 2026-2027 given the new consultation paper IRDA has put out; management said the economics of the business "will be undergoing a very radical change" and is waiting for IRDA's final agreements; insurance remains EBITDA-negative, so slower growth helps HealthCo EBITDA.
• HealthCo intent to increase daily orders by ~20-30% over the next 6 months — through ~Q4 FY 2026-2027, per CEO Madhivanan Balakrishnan, with a broadly stable cost structure; goal is first parity with the offline pharmacy business on pre-OPX margin, then at EBITDA level, as part of an omni-channel strategy.

Near-Term Margin Dip; Demerger on Track for Q4 FY27

• HealthCo (pro forma combined) EBITDA margin now expected at ~6% by end of Q4 FY27 — versus 6.5-7% indicated earlier for the entity; CFO Sanjeev Gupta said the business is still expected to move to a higher single-digit margin over the next 3-4 years (i.e., by ~FY 2030-2031).
• Integrated HealthCo business EBITDA guided at ~Rs.1,500 crore+ for FY 2026-2027 — near-term margin dip attributed to manpower investment across pharmacy, private label and generics lines, employee bonus paid in FY 2026-2027, and one-time scheme/integration-related expenses.
• Additional one-time costs expected in Q3 and Q4 FY 2026-2027 — as the company moves toward NCLT approval of the scheme and listing; from FY 2027-2028 onwards these one-time items will not recur and the margin percentage is expected to move up.
• Demerger expected to complete in Q4 FY 2026-2027 — the proposed strategic restructuring of the omnichannel pharmacy and digital health business is on schedule as planned, framed as a step toward a scaled integrated healthcare platform and unlocking long-term shareholder value.
• Existing-hospital margins at ~26% in Q2 FY 2026-2027 — the guided 100bps margin expansion in the existing network came through in FY 2026-2027; MD Suneeta Reddy said further expansion will be a combination of the existing network and new hospitals ramping up.
• 1 new hospital (Hyderabad) already at EBITDA break-even as of Q2 FY 2026-2027 — the other 3 will break even by end of FY 2026-2027.

Hospital Legislation, Price Cap and Pricing-Model Engagement

• Proposed hospital legislation will impact both small and large hospitals — MD Suneeta Reddy said Apollo is willing to work with the government to build more hospitals and beds, stressing that hospitals are a long-horizon investment and predictable regulation is essential to attract the capital the sector requires.
• Management cited India's need for 1.3 million additional beds, 1 million doctors and 3.5 million nurses — period unspecified, against only 170,000 private healthcare beds currently available in India; affordability is improving with rising insurance penetration.
• Management's message to the government on pricing — product pricing (e.g., cancer medicines, consumables) is not a cost-plus model; product pricing was a proxy for the service delivered, and it hopes to move to service-based pricing while continuing to engage with the government.
• Supreme Court engagement expected to continue — management said the government has represented its case very strongly in the Supreme Court; no quantified margin impact was provided for the hospital business.
• Pharmacy price cap effective from November 9, 2026 (Q3 FY 2026-2027) — CFO Sanjeev Gupta said the company is awaiting revised MRPs to analyze the impact; some impact is expected and will be quantified once the price cap becomes effective.

Growth Trajectory, Guidance Context and H2 Priorities

• Bank of America's Neha Manpuria asked whether hospital growth can run closer to 20% — vs management's high-teens guidance for FY 2026-2027, noting existing hospitals grew high teens over Q1-Q2 FY 2026-2027 against an expected mid-teens pace; MD Suneeta Reddy declined to make a forward-looking statement on 20% growth but cited strong structural healthcare demand, pan-India network accessibility, and average revenue per patient of Rs.1.8 lakhs.
• Management asked for ~2 quarters (through ~Q4 FY 2026-2027) before HealthCo margin stabilization — unit economics continue to improve, order volumes are building, and mix is improving (private label, generics, others) with more offline-online synergies; management endorsed the view that margin improvement should be consistent as the insurance drag fades.
• H2 FY 2026-2027 outlook — focus on sustaining healthcare services growth, scaling digital and retail platforms profitably, and progressing the expansion program with disciplined capital allocation.
• Sector momentum is industry-wide, not company guidance — management noted the broader healthcare sector is witnessing strong momentum with players across the industry reporting healthy volumes and revenue growth, increased participation and investment inflows; international patient momentum was cited as validation of India's potential as a global healthcare destination, aligned with the government's "Heal in India" vision.
• Closing framing — management (Suneeta Reddy) said Q2 FY27 and H1 FY27 reflect the strength of the business and progress across the integrated healthcare platform, with structural demand, clinical excellence, technology and capacity investments providing a strong foundation for the next phase of growth.